Clinical Trials
As a service to physicians, researchers, patients, and families, the registry has compiled a list of selected peer-reviewed references related to dipg. this list is for information only. the registry does not endorse or recommend any of the specific conclusions or approaches to therapy described.
Abstracts and additional information available by selecting the links to ClinicalTrials.gov, a service of the US National Library of Medicine and the National Institutes of Health.
| Title | Phase | Recruitment | Conditions | Interventions | Sponsors | Expected Completion Date |
|---|---|---|---|---|---|---|
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | Phase 1 | Recruiting | Medulloblastoma, Astrocytoma, Grade III, Glioblastoma, Anaplastic Astrocytoma, Brain Stem Neoplasms, Malignant, Oligodendroblastoma, Anaplastic Oligodendroglioma , Malignant Glioma | Drug: Mebendazole | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | June 2022 |
| A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3 | Phase 1 | Not yet recruiting | Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG, High-grade Astrocytoma NOS, CNS Primary Tumor, NOS (Malignant Glioma) | Drug: INCB7839 | Pediatric Brain Tumor Consortium | December 31, 2023 |
| A Phase I Study Examining the Feasibility of Intermittent Convection-Enhanced Delivery (CED) of MTX110 for the Treatment of Children With Newly Diagnosed Diffuse Midline Gliomas | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma | Drug: Infusate with MTX110 and gadolinium Device: Convection-Enhanced Delivery (CED) | Stergios Zacharoulis | February 2024 |
| Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | Phase 1 | Recruiting | Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma | Biological: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel | Seattle Children's Hospital | May 2041 |
| PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE (REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS | Phase 1 | Recruiting | Solid Tumors; Ewing Sarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma | Drug: Palbociclib; Drug: Temozolomide; Drug: Irinotecan | Pfizer | December 3, 2023 |
| A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors | Phase 1 | Active, not recruiting | Neoplasms | Drug: BXQ-350 | Bexion Pharmaceuticals, Inc. | November 2020 |
| A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors | Phase 1 | Recruiting | Primary Central Nervous System Neoplasm; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Refractory Diffuse Intrinsic Pontine Glioma; Refractory Malignant Glioma; Refractory Medulloblastoma | Drug: Savolitinib | National Cancer Institute (NCI) | December 31, 2020 |
| A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors | Phase 1 | Recruiting | Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor; DIPG; Neuroblastoma; Ewing Sarcoma; Rhabdomyosarcoma; Osteosarcoma | Drug: CLR 131 | Cellectar Biosciences, Inc. | December 2020 |
| Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B) | Phase 1 | Not yet recruiting | Diffuse Intrinsic Pontine Glioma; High Grade Glioma | Genetic: (C7R)-GD2.CART cells; Drug: Cyclophosphamide; Drug: Fludarabine | Baylor College of Medicine; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine | December 2034 |
| A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG) | Early Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma; Recurrent Anaplastic Astrocytoma; Recurrent Glioblastoma; Recurrent Malignant Glioma; Recurrent Medulloblastoma | Drug: Fimepinostat; Procedure: Therapeutic Conventional Surgery | Sabine Mueller, MD, PhD; Pacific Pediatric Neuro-Oncology Consortium; Cannonball Kids' Cancer Foundation; Curis, Inc. | June 2027 |
| Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG | Phase 2 | Recruiting | Glioblastoma; Medulloblastoma; Ependymoma; Diffuse Intrinsic Pontine Glioma | Drug: Indoximod; Radiation: Partial Radiation; Radiation: Full-dose Radiation; Drug: Temozolomide; Drug: Cyclophosphamide; Drug: Etoposide; Drug: Lomustine | Theodore S. Johnson; National Cancer Institute (NCI); Augusta University; Emory University | October 2, 2026 |
| Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM) | Phase 1 | Enrolling by invitation | Diffuse Intrinsic Pontine Glioma or Glioblastoma | Biological: Immunomodulatory DC vaccine to target DIPG and GBM | Shenzhen Geno-Immune Medical Institute | December 31, 2022 |
| Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma | Not Applicable | Enrolling by invitation | Recurrent Diffuse Intrinsic Pontine Glioma | Radiation: Hypofractionated Radiotherapy | University of Cincinnati; Children's Hospital Medical Center, Cincinnati | July 31, 2023 |
| The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma | Phase 1 | Active, not recruiting | Recurrent Medulloblastoma; Recurrent Brain Tumor, Childhood; Malignant Glioma | Drug: PEP-CMV | Gary Archer Ph.D. | June 2022 |
| A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma | Phase 1; Phase 2 | Recruiting | Relapsed Solid Tumor; Refractory Solid Tumor; Relapsed Central Nervous System Tumor; Refractory Central Nervous System Tumor; Diffuse Intrinsic Pontine Glioma; High Grade Glioma | Drug: REGN2810 (monotherapy); Drug: REGN2810 (maintenance); Radiation: Conventional or hypofractionated; Radiation: Re-irradiation | Regeneron Pharmaceuticals | October 2, 2024 |
| International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) | Phase 3 | Recruiting | Glioblastoma WHO Grade IV; Diffuse Midline Glioma Histone 3 K27M WHO Grade IV; Anaplastic Astrocytoma WHO Grade III; Diffuse Intrinsic Pontine Glioma; Gliomatosis Cerebri | Drug: Temozolomide + Valproic Acid; Drug: Temozolomide + Chloroquine | University of Göttingen | June 1, 2023 |
| Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy | Phase 1 | Recruiting | Brain and Central Nervous System Tumors | Drug: GDC-0084; Radiation: radiation therapy | St. Jude Children's Research Hospital | June 2024 |
| Phase 2 Randomized Study of RT and Reirradiation at Relapse vs Multiple Elective RT Courses With Same Concomitant CT for Newly Diagnosed | Phase 2 | Recruiting | Diffuse Intrinsic Pontine Glioma | Drug: Nimotuzumab; Drug: Vinorelbine; Other: Radiotherapy | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | November 2, 2024 |
| A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | Phase 1 | Recruiting | High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Drug: PTC596 | Children's Hospital Medical Center, Cincinnati | July 1, 2027 |
| Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers | Not Applicable | Recruiting | Gliomas; Glioblastomas; Astrocytoma; Brain Neoplasm; Brain Cancer | Behavioral: Enhanced Mindfulness Intervention; Behavioral: Psychoeducation | National Cancer Institute (NCI) | April 1, 2020 |
| Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO) | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma (DIPG) | Biological: TTRNA-DC vaccines with GM-CSF; Biological: TTRNA-xALT; Drug: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning; Drug: Dose-Intensified TMZ; Drug: Td vaccine; Biological: Autologous Hematopoietic Stem Cells (HSC) | University of Florida | June 2022 |
| MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015) | Phase 1; Phase2 | Recruting | Diffuse Intrinsic Pontine Glioma | Drug: Panobinostat Nanoparticle Formulation MTX110; Drug: Convection-Enhanced Delivery (CED) | Sabine Mueller, MD, PhD | September 1, 2020 |
| A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors | Phase 1 | Recruiting | Central Nervous System Embryonal Tumor, Not Otherwise Specified; Malignant Glioma;Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Childhood Ependymoma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma; Refractory Diffuse Intrinsic Pontine Glioma | Drug: Everolimus; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Ribociclib | Pediatric Brain Tumor Consortium | July 31, 2020 |
| Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma | Phase 1 | Recruiting | Glioblastoma Multiforme; High-grade Astrocytoma NOS; CNS Primary Tumor, Nos; Ependymoma, NOS; Diffuse Intrinsic Pontine Gliomas (DIPG); Medulloblastoma | Biological: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients; Biological: APX005M treatment for newly diagnosed DIPG patients | Pediatric Brain Tumor Consortium; St. Jude Children's Research Hospital;American Lebanese Syrian Associated Charities; The Cancer Therapy Evaluation Program of the National Cancer Institute; Apexigen, Inc.; Solving Kids’ Cancer; Ty Louis Campbell Foundation; A Kids Brain Tumor Cure | September 30, 2022 |
| A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | Phase 2 | Active, not recruiting | Central Nervous System Neoplasms; Medulloblastoma | Drug: Pomalidomide | Celgene | March 18, 2023 |
| A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors | Phase 1 | Recruiting | Glioblastoma Multiforme; Glioma; Gliosarcoma; Malignant Brain Tumor; Ependymoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma; Primary CNS Tumor | Drug: Indoximod; Drug: Temozolomide; Radiation: Conformal Radiation; Drug: Cyclophosphamide; Drug: Etoposide | NewLink Genetics Corporation | May 2020 |
| ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma; Glioma, Malignant | Drug: ONC201 | Oncoceutics, Inc. | July 24, 2020 |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG | Phase 1 | Recruiting | Pediatric Brain Tumor; Diffuse Intrinsic Pontine Glioma | Biological: Ad-RTS-hIL-12; Drug: oral veledimex | Ziopharm | March 2021 |
| Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations | Phase 2 | Recruiting | Glioma | Drug: Dasatinib Drug: Everolimus | University of Michigan Cancer Center | December 1, 2025 |
| A Phase I Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma Malignant Glioma of Brain High Grade Glioma Bithalamic High Grade Glioma Brainstem Glioma Glioblastoma Anaplastic Astrocytoma | Drug: Ribociclib Drug: Everolimus | Children's Hospital Medical Center, Cincinnati Novartis | January 1, 2022 |
| A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging With Gadolinium in Children With Diffuse Intrinsic Pontine Glioma | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma | Drug: Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI) | University of California, San Francisco The V Foundation for Cancer Research Pacific Pediatric Neuro-Oncology Consortium | September 2021 |
| A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children With Newly Diagnosed DIPG | N/A | Active, not recruiting | Diffuse Intrinsic Pontine Glioma (DIPG) | Other: Specialized tumor board recommendation Radiation: Standard radiation therapy | University of California, San Francisco Translational Genomics Research Institute | May 2020 |
| International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository | Observational | Recruiting | Diffuse Intrinsic Pontine Glioma | Cincinnati Children's Hospital Medical Center | June 2037 | |
| Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy | Phase I | Recruiting | Brain Cancer|Brain Stem Glioma | Radiation: Radioactive iodine-labeled monoclonal antibody 8H9 | Memorial Sloan-Kettering Cancer Center|Weill Medical College of Cornell University|Johns Hopkins University | December 2018 |
| An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) | Phase 2 | Active, not recruiting | Diffuse Intrinsic Pontine Glioma (DIPG) | Biological: Nivolumab Biological: Ipilimumab | Bristol-Myers Squibb | June 14, 2021 |
| PNOC 007: H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma, Glioma | Biological: K27M peptide | University of California, San Francisco; The V Foundation for Cancer Research; Pacific Pediatric Neuro-Oncology Consortium | November 2020 |
| Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma | Early Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma | Drug: Gemcitabine | University of Colorado, Denver | December 2021 |
| ADVL1217: WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | Phase 1 | Active, not recruiting | Diffuse Intrinsic Pontine Glioma Untreated Childhood Anaplastic Astrocytoma Untreated Childhood Anaplastic Oligoastrocytoma Untreated Childhood Glioblastoma Untreated Childhood Gliosarcoma | Drug: WEE1 Inhibitor AZD1775 | National Cancer Institute (NCI) | October 2021 |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE) | Phase 2 | Recruiting | Diffuse Intrinsic Pontine Glioma | Drug: Erlotinib Drug: Everolimus Drug: Dasatinib | Gustave Roussy, Cancer Campus, Grand Paris; Innovative Therapies For Children with Cancer Consortium | October 2018 |
| Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Phase 1 Phase 2 | Active, not recruiting | High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma | Drug: Ribociclib | Cincinnati Children's Hospital Medical Center | January 2018 |
| PBTC-047 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma | Phase 1 | Recruiting | Glioma | Drug: LBH589 (Panobinostat) | Pediatric Brain Tumor Consortium | October 1, 2019 |
| Pediatric MATCH | Phase 2 | Recruiting | Malignant Glioma, Recurrent Central Nervous System Neoplasm, Recurrent Glioma | Drug options: Ensartinib, Larotrectinib, Olaparib,pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 PI3K/mTOR Inhibitor LY3023414,Selumetinib Sulfate, Tazemetostat, Vemurafenib | National Cancer Institute (NCI) | December 31, 2021 |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | Phase 1 Phase 2 | Recruiting | Glioblastoma Multiforme Fibrillary Astrocytoma of Brain Glioma of Brainstem Anaplastic Astrocytoma Pilomyxoid Astrocytoma Mixed Oligodendroglioma-Astrocytoma Brain Stem Glioma Diffuse Intrinsic Pontine Glioma | Erbitux and Bevacizumab | Weill Medical College of Cornell University | January 2025 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, or Hypermutated Brain Tumors | Phase 1 | Recruiting | Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Diffuse Intrinsic Pontine Glioma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma | Biological: Pembrolizumab | National Cancer Institute (NCI) | April 1, 2020 |
| Re-Irradiation of Progressive or Recurrent DIPG | N/A | Recruiting | Recurrent or Progressive Diffuse Intrinsic Pontine Glioma | Radiation: re-irradiation | University of Calgary | October 2021 |
| An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations | Phase 1 | Recruiting | Solid including primary brain tumors and DIPGs | Drug: Trametinib, Drug: Dabrafenib | GlaxoSmithKline | October 2020 |
| Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma | Other: Laboratory Biomarker Analysis Drug: Vorinostat Radiation: Radiation Therapy Drug: Temsirolimus | M.D. Anderson Cancer Center | October 31, 2020 |
| Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Glioblastoma (GBM); DIPG | Drug: Doxorubicin | Meyer Children's Hospital | July 2020 |
| Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines | Phase 1 | Active, not recruiting | Diffuse Intrinsic Pontine Glioma | Biological: Autologous dendritic cells | Fundació Sant Joan de Déu; Institut d'Investigacions Biomèdiques August Pi i Sunyer | March 2019 |
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | Phase 1 Phase 2 | Recruiting | Pilomyxoid Astrocytoma Pilocytic Astrocytoma Glioma, Astrocytic Optic Nerve Glioma Pleomorphic Xanthoastrocytoma Glioblastoma Multiforme Anaplastic Astrocytoma Gliosarcoma Diffuse Intrinsic Pontine Glioma DIPG Low-grade Glioma Brainstem Glioma | Drug: Mebendazole Drug: Vincristine Drug: Carboplatin Drug: Temozolomide Drug: Bevacizumab Drug: Irinotecan | Mark Atlas; Janssen Pharmaceuticals; Northwell Health | April 2020 |
| Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma Brain Tumor, Recurrent Solid Tumor, Recurrent Neuroblastoma, Recurrent, Refractory Ewing Sarcoma, Recurrent, Refractory Rhabdomyosarcoma, Recurrent, Refractory Osteosarcoma, Recurrent, Refractory Rhabdoid Tumor, Recurrent, Refractory | Drug: Abemaciclib | Children's Healthcare of Atlanta/Emory University | December 2020 |
| Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Recurrent or Refractory Brain Tumors | Phase 1 | Active, Not Recruiting | Astrocytoma Childhood Atypical Teratoid/Rhabdoid Tumor Diffuse Intrinsic Pontine Glioma Glioma Recurrent Childhood Anaplastic Oligodendroglioma Recurrent Childhood Brain Neoplasm Recurrent Childhood Glioblastoma Recurrent Childhood Medulloblastoma Recurrent Primitive Neuroectodermal Tumor Refractory Brain Neoplasm | Biological: Sargramostim Biological: Wild-type Reovirus | Mayo Clinic | April 2020 |
| Molecular Analysis of Samples from Patients with Diffuse Intrinsic Pontine Glioma and Brainstem Glioma | Observational | Recruiting | Diffuse Intrinsic Pontine Glioma|Brainstem Glioma | Not applicable | Children's Research Institute | April 2030 |
